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high fat + 1,25(OH)2D3, or LPS + high fat + 1,25(OH)2D3. 
RNA and protein were extracted to detect the expression 
of TLR4 and downstream inflammatory factors such as 
NF-ΚB, TNF-α, and IL-6. Groups of data were compared 
by single factor variance analysis.
Results High-dose 1,25(OH)2D3 administration for 
16 weeks downregulated the expression of TLR4, NF-κB, 
and TNF-α in the liver tissue of diabetic rats and attenuated 
hepatic inflammation and fibrosis, as shown by immunohis-
tochemical staining, hematoxylin and eosin staining, Mas-
son’s trichrome staining, reverse transcription polymerase 
chain reaction (RT-PCR), and western blotting. In vitro, 
hepatocytes treated with high fat or LPS exhibited signifi-
cantly increased expression of TLR4, NF-κB, and down-
stream inflammatory factors (P < 0.05). Intervention with 
1,25(OH)2D3 decreased the expression of TLR4, NF-κB, 
and inflammatory factors (P < 0.05).
Conclusions 1,25(OH)2D3 exhibited protective effects 
against diabetes-related liver injury, possibly through 
downregulation of components of the TLR4 signaling 
pathway.
Keywords Diabetes · 1,25(OH)2D3 · Inflammation ·  
Toll-like receptor 4 · Hepatocytes · Liver injury
Introduction
Diabetes mellitus (DM) is a serious disease in which 
chronic complications can cause multiple organ injuries, 
including damage to the liver [1]. Accumulation of fatty 
acids, particularly saturated fatty acids in the liver can 
activate a number of pro-inflammatory signaling path-
ways, including the Toll-like receptor (TLR) pathway [2]. 
Unlike other TLRs, TLR4 can bind to endogenous ligands 
Abstract 
Background Fatty acid deposition in the liver can activate 
a number of pro-inflammatory signaling pathways such as 
the Toll-like receptor 4 (TLR4) pathway, which may be 
important in the pathogenesis of nonalcoholic steatohepa-
titis. 1,25(OH)2D3 downregulates the expression of TLR4 
and may represent a novel treatment strategy for reducing 
hepatocyte injury. Therefore, in this study, we investigated 
the protective effects of 1,25(OH)2D3 on diabetic liver 
injury in vivo.
Methods Streptozotocin (STZ)-induced diabetic rats 
were randomly divided into five groups and treated with 
low-dose 1,25(OH)2D3 (0.025 μg/kg/day), medium-dose 
1,25(OH)2D3 (0.15 μg/kg/day), high-dose 1,25(OH)2D3 
(0.3 μg/kg/day), insulin (protamine zinc insulin 16 U/kg/
day, subcutaneous injection), or no intervention (the control 
group). Sixteen weeks later, the rats were killed, and blood 
samples were obtained to test lipid profiles and hepatic 
function. The infiltration of inflammatory cells, the level of 
fibrosis, and the expression levels of TLR4, nuclear factor-
kappa B (NF-κB), and tumor necrosis factor-α (TNF-α) in 
the liver were analyzed. The hepatocytes were treated with 
vehicle control, LPS (100 ng), high fat [DMEM + FFA 
(0.1 mM: palmitic acid, oleic acid, 1:2)], LPS + high fat, 
vehicle + 1,25(OH)2D3 (10−7 M), LPS + 1,25(OH)2D3, 
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associated with cell injury, such as inflammatory media-
tors/factors [2, 3]. Additionally, the TLR4 signaling path-
way can activate nuclear factor-kappa B (NF-κB) and 
induce the expression of pro-inflammatory genes. These 
changes promote recruitment and activation of inflamma-
tory cells, thereby resulting in the activation of inflamma-
tion and fibrosis [4, 5].
Studies have shown that TLR activation and vitamin D 
deficiency play important roles in the pathogenesis of type 
1 diabetes mellitus (T1DM) [6, 7]. Indeed, the expression 
of TLR4 is increased in monocytes from patients with 
T1DM compared with healthy controls [6]. Moreover, 
patients with T1DM and T1DM with microvascular com-
plications are significantly vitamin D deficient compared 
with control subjects [7]. Interestingly, there is a negative 
correlation between TLR4 expression and serum concentra-
tion of 25(OH)D3. In monocytes from patients with T1DM 
pretreated for 24 h with 1,25(OH)2D3 (0.1 µM), the expres-
sion of TLR4 and cytokines in response to lipopolysaccha-
ride is decreased [7]. However, few studies have investi-
gated the effects of vitamin D on nonalcoholic fatty liver 
disease (NAFLD) in vivo, either by sunlight therapy or by 
vitamin D supplementation to the diet in order to increase 
the serum level of 25(OH)D3. To avoid the effects of unsta-
ble vitamin D on serum vitamin D levels and to prevent 
the hydroxylation of vitamin D to 1,25(OH)2D3 both in the 
liver and kidney, we used 1,25(OH)2D3, the active form of 
vitamin D in vivo, and investigated the protective effects of 
1,25(OH)2D3 on diabetic liver injury.
Materials and methods
Chemicals
Streptozotocin (STZ) and 1,25(OH)2D3 were purchased 
from Sigma–Aldrich (St. Louis, MO, USA). Polyclonal 
antibodies targeting rat TLR4, TNF-α, NF-κB p65, 
phospho-NF-κB, and β-actin were purchased from Cell 
Signaling Technology (Danvers, MA, USA). Protamine 
zinc insulin (P) was obtained from Jiangsu Wanbang Bio-
logical Technology Ltd. (Xuzhou, Jiangsu, China). CD68 
was purchased from Wuhan Boster Biological Technology 
Ltd. (Wuhan, Hubei, China).
Animals and treatments
All experimental procedures were performed in accordance 
with the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals and were approved by the 
Animal Care and Use Committee of Tianjin Medical Uni-
versity (Tianjin, China). Ninety 8-week-old male Sprague–
Dawley (SD) rats, with body weights ranging from 180 to 
220 g, were obtained from Beijing Huafukang Biological 
Science and Technology Stock Co. Ltd. (Beijing, China). 
The animals were maintained in a room with controlled 
temperature (21 ± 2 °C) and a 12:12-h light–dark cycle, 
with free access to food pellets (standard rat chow) and 
tap water. Eighty rats were given single injections of STZ 
(45 mg/kg) into the tail vein. Seventy-five of these rats 
subsequently acquired diabetic symptoms, having blood 
glucose concentrations greater than 16.7 mM, and under-
went further treatment for 16 weeks. The remaining ten rats 
that did not receive STZ injection were treated with 0.1 M 
sodium citrate buffer as vehicle and were designated as the 
normal control group (Group C).
Diabetic rats were divided randomly into five groups: 
Group D, with untreated diabetes mellitus; Group H, treated 
with high-dose 1,25(OH)2D3 (0.3 µg/kg/day); Group M, 
treated with medium-dose 1,25(OH)2D3 (0.15 µg/kg/day); 
Group L, treated with low-dose 1,25(OH)2D3 (0.025 µg/
kg/day); and Group I, treated with insulin (protamine zinc 
insulin, 16 U/kg/day, subcutaneous injection). 1,25(OH)2D3 
was administrated daily by oral gavage in rats at 09:00 h. 
Standard rat chow, containing 48 % corn, 20 % soybean 
meal, 10 % wheat bran, 10 % flour, 8 % fish meal, 2 % 
farina, 1 % vegetable oil, 0.5 % salt, and 0.5 % trace ele-
ments, was provided to all groups of rats.
Biochemical and histological analysis
Sixteen weeks after induction of diabetes, all rats were 
weighed and euthanized. The day before euthanasia, the 
rats were fasted overnight from 20:00 h, and blood sam-
ples were obtained at 08:00 h on the following day. Analy-
sis of glucose, alanine aminotransferase (ALT), C-reactive 
protein (CRP), total cholesterol (TC), triglycerides (TG), 
low-density lipoprotein (LDL), calcium, and phosphorus 
in plasma samples was performed using standard enzy-
matic techniques (Hitachi 7600 Automatic Biochemistry 
Analyzer, Hitachi, Japan). After euthanasia, the livers were 
removed, and half of each liver was fixed in 10 % buffered 
formalin and embedded in paraffin. Formalin-fixed liver 
tissue was processed for histological analysis, including 
immunohistochemical staining with different antibodies 
or hematoxylin and eosin staining (H&E) or Masson’s tri-
chrome staining to detect collagen for evaluation of fibro-
sis. The remaining liver tissues were stored at −80 °C until 
use for RNA and protein extraction and subsequent reverse 
transcription polymerase chain reaction (RT-PCR) and 
western blotting analyses.
Isolation of hepatocytes
Four-month-old male SD rats (150–200 g) were pur-
chased from Beijing Huafukang Biological Science and 
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Technology Stock Co. Ltd. (Beijing, China). A vertical 
incision on the left side of abdomen was made to expose the 
portal vein and inferior vena cava. Then, a 24-gauge cath-
eter was inserted into the portal vein for perfusion. Hepato-
cytes were isolated from the livers of SD rats with HBSS 
(5.33 mM KCl, 0.44 mM KH2PO4, 0.34 mM Na2HPO4, 
138 mM NaCl, and 4.17 mM NaHCO3, adjusted to pH 7.5–
8.0) containing 0.5 mM EDTA to remove blood. Cells were 
then treated with 0.05 % collagenase IV in Dulbecco’s 
modified Eagle’s medium (DMEM, 5.5 mM glucose; Inv-
itrogen, USA). Primary hepatocytes were cultured at a den-
sity of 2–6 × 105 cells per dish in DMEM supplemented 
with 5 % fetal bovine serum (Gibco, USA), 1 % l-glu-
tamine, 1 % nonessential amino acids, and 1 % penicillin–
streptomycin (Invitrogen, USA) at 37 °C in an atmosphere 
containing 5 % CO2. After incubation for 24 h, cells were 
adherent and split in six-well plates. Primary hepatocytes 
were divided randomly into seven groups: Group C, normal 
control group; Group L, treated with LPS (Sigma, USA) 
(100 ng); Group F, treated with DMEM containing high 
fat and FFAs (0.1 mmol, palmitic acid: oleic acid = 1:2; 
Sigma, USA); Group L + F, treated with LPS and high 
fat; Group L + VD, treated with LPS and 1,25(OH)2D3 
(10−7 M; Sigma); Group F + VD, treated with high fat and 
1,25(OH)2D3; and Group L + F + VD, treated with LPS, 
high fat, and 1,25(OH)2D3. Cells were harvested for quanti-
tative RT-PCR and western blot analysis.
RT‑PCR
Total RNA was prepared using TRIzol reagent (Invitro-
gen, Carlsbad, CA, USA), according to the manufacturer’s 
instructions. RNA was reverse-transcribed into comple-
mentary DNA (cDNA) by using a SuperScript First-Strand 
Synthesis System for RT-PCR Kit (Invitrogen), and the 
cDNA fragments were amplified by PCR with Taq DNA 
polymerase (Invitrogen). PCR was carried out in a thermal 
cycler (Bio-Rad, Hercules, CA, USA). Initial denaturation 
was carried out at 95 °C for 15 min, followed by 40 cycles 
of denaturation for 10 s at 95 °C, annealing for 30 s at the 
appropriate temperature, and extension for 32 s at 72 °C. 
The primer sequences used for PCR were as follows: 
β-actin, forward 5′-CCTCATGCCATCCTGCGTCTG-3′ 
and reverse 5′-TTGCTCGAAGTCTAGGGCAACATAG-3′ 
(annealing temperature: 58 °C); TLR4, forward 
5′-GCCTTGAATCCAGATGAAAC-3′ and reverse 5′-CT 
GTGAGGTCGTTGAGGTTAG-3′ (annealing tempera-
ture: 58 °C); NF-κB, forward 5′-TCCCCTGTACGA 
TAGTCGGCTC-3′ and reverse 5′-GAGCGTTGCTTTGGA 
TCAAGG-3′ (annealing temperature: 60 °C); TNF-α, 
forward 5′-GAAAAGCAAGCAACCAGCCA-3′ and 
reverse 5′-CGGATCATGCTTTCCGTGCTC-3′ (annealing 
temperature: 57 °C); and IL-6, forward 5′-CTGGCAATATG 
AATGTTGAAAC-3′ and reverse 5′-AGAAACCATCTGG 
CTAGGTAAG-3′ (annealing temperature: 58 °C).
Western blotting
The levels of TLR4, TNF-α, NF-κB p65, and phospho-
NF-κB in liver tissue and hepatocytes were analyzed by 
western blotting. Proteins were extracted using RIPA buffer 
(Thermo, USA), according to the manufacturer’s instruc-
tions, and the protein concentrations were measured using 
a BCA protein assay kit (Thermo, USA). An equal amount 
of protein from each sample was subjected to sodium dode-
cyl sulfate (SDS)-polyacrylamide gel electrophoresis and 
then transferred to polyvinylidene difluoride (PVDF) mem-
branes (Bio-Rad). Membranes were blocked with 5 % milk 
in 1 × Tris-buffered saline with 0.1 % Tween-20 (TBST) 
for 1 h at room temperature and incubated overnight at 4 °C 
with primary antibodies. Membranes were washed twice 
for 10 min in 1 × TBST and then incubated with horse-
radish peroxidase (HRP)-conjugated secondary antibodies 
for 2 h. Membranes were then washed twice for 10 min in 
1 × TBST. Proteins were visualized by ECL (Millipore), 
and blots were scanned using a Fluor-S MAX MultiImager 
System (Bio-Rad). The signal intensities were determined 
using Quantity One image software (Bio-Rad).
Statistical analysis
Normally distributed data were expressed as the 
mean ± standard deviation (SD). Statistical analysis was 
performed using analysis of variance (ANOVA) for multi-
ple group comparisons. SPSS 19.0 statistical software was 
used for data analysis, and differences with P values less 
than 0.05 were considered significant.
Results
Plasma concentrations of biochemical parameters 
in rats
Biochemical parameters for the different groups of rats 
are shown in Table 1. Compared with Group C, the body 
weights and liver weights of diabetic rats in Groups D, L, 
M, and H were significantly decreased. Additionally, glu-
cose levels were higher in rats in Group D than in those 
of the other groups, demonstrating that rats administered 
1,25(OH)2D3 or insulin exhibited reduced blood glucose 
levels. ALT levels in rats of all five diabetic groups were 
higher than those in rats of Group C. Moreover, compared 
with rats in Group D, rats in Groups H and I exhibited sig-
nificantly reduced ALT levels (P < 0.05). Compared with 
the control group, levels of ALB in diabetic rats decreased 
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significantly (P < 0.05). Interestingly, serum calcium 
tended to increase in the three groups of rats treated with 
1,25(OH)2D3; however, these differences were not signifi-
cant (P > 0.05). The same trend was observed for serum 
phosphate. Compared with Group C rats, Group D rats 
showed an increase in serum CRP levels (P < 0.05). More-
over, compared with rats in Group D, rats in Groups H and 
M showed significantly reduced CRP levels (P < 0.05). 
No significant differences were observed for TC levels in 
all groups of rats (P > 0.05); however, TC levels tended 
to decrease in rats treated with 1,25(OH)2D3. In addition, 
compared with the levels of TG in Group C rats, those 
in Group D rats were significantly increased (P < 0.05), 
while those in Group H rats were significantly decreased 
(P < 0.05). Finally, rats in Group D showed significantly 
higher levels of LDL than did rats in Group C, and LDL 
levels were dramatically decreased in rats treated with 
1,25(OH)2D3, particularly in rats of Groups M and H 
(P < 0.05).
Histological findings of liver tissues in rats
As shown in H&E-stained sections in Fig. 1, there was no 
obvious inflammatory cell infiltration in Group C, and only 
minor punctate changes in the portal area were observed. 
Obvious inflammatory cell infiltration around hepatocytes, 
degeneration of hepatocytes, and diffuse infiltration around 
the portal vein were observed in Group D. In Group I, infil-
tration of inflammatory cells was observed, accompanied 
by different levels of hepatic steatosis, although not to the 
extent observed in Group D. Lesions in Group L were simi-
lar to those in Group D. However, interestingly, Group H 
exhibited reduced infiltration of inflammatory cells and a 
clear arrangement and structure of hepatocytes. The infil-
tration of inflammatory cells in Group M was less than that 
in Group L, but more than that in Group H, consistent with 
the dose of vitamin D (Fig. 1a).
Using Masson’s trichrome staining (Fig. 1b), weak sig-
nal accumulation (green coloration) appeared along the 
vascular wall of the portal vein and portal area in Group C. 
However, no obvious coloration was observed around sinu-
soidal spaces and cells. In contrast, staining was observed 
around sinusoidal spaces and cells in the portal area in 
Group D. Moreover, the structure of the hepatic lobule 
was abnormal. In Group I, the level of interstitial fibrosis 
decreased, and fibrosis was mainly present around sinu-
soidal spaces. Tissues from Group L resembled those from 
Group D, and the level of fibrosis observed in tissues from 
Group M was much lower than that in Group L. Finally, the 
lowest level of fibrosis was observed in Group H, in which 
the liver structure was normal and intact (Fig. 1b).
Immunohistochemical staining
Next, we examined the immunohistochemical staining 
patterns of TLR4 components in tissues from each group 
of rats. TLR4 expression was observed only in a few 
hepatocytes in Group C tissues. However, TLR4 expres-
sion was observed on the membranes of hepatocytes and 
Kupffer cells in Group D tissues. Tissues from Group L 
Table 1  Biochemical parameters for rats evaluated in this study
C control, D diabetes, L low dose, M medium dose, H high dose, I insulin
* Compared with Group C, P < 0.05
# Compared with Group D, P < 0.05
▼ Compared with Group I, P < 0.05
Groups
C (n = 10) C (n = 10) C (n = 10) C (n = 10) C (n = 10) C (n = 10)
Body weight (g) 440.70 ± 9.89#,▼ 289.50 ± 23.51*,▼ 289.10 ± 19.66*,▼ 293.50 ± 22.04*,▼ 302.30 ± 18.83*,▼ 399.90 ± 27.16*,#
Liver weight (g) 12.49 ± 2.47#,▼ 6.66 ± 0.79* 6.93 ± 0.62* 7.85 ± 0.85* 8.21 ± 1.61* 8.1 ± 0.65*
Glucose (mM) 6.24 ± 0.50 # 29.00 ± 4.22*,▼ 26.93 ± 3.80*,▼ 24.73 ± 3.53*,#,▼ 21.98 ± 1.19*,#,▼ 7.75 ± 0.96 #
ALB (g/L) 44.4 ± 4.69# 31.7 ± 5.08*,▼ 43.0 ± 6.18# 41.8 ± 4.54# 44.8 ± 6.18# 41.3 ± 6.58#
ALT (U/L) 49.5 ± 8.07#,▼ 83.3 ± 13.8*,▼ 76.7 ± 8.38*,▼ 89.8 ± 13.4*,▼ 70.3 ± 13.1*,# 64.4 ± 13.8*,#
Serum calcium 
(mM)
2.28 ± 0.24 2.24 ± 0.43 2.41 ± 0.25 2.46 ± 0.23 2.32 ± 0.26 2.34 ± 0.33
Serum phosphate 
(mM)
2.53 ± 0.42 2.66 ± 0.25 2.43 ± 0.11 2.63 ± 0.12 2.46 ± 0.41 2.51 ± 0.11
CRP (mg/dL) 1.08 ± 0.14# 1.32 ± 0.17* 1.2 ± 0.23 1.06 ± 0.08# 1.06 ± 0.18# 1.18 ± 0.15
TG (mM) 0.79 ± 0.20#,▼ 1.29 ± 0.19* 1.30 ± 0.30* 1.15 ± 0.34* 0.91 ± 0.29# 1.10 ± 0.30*
TC (mM) 1.06 ± 0.08 1.50 ± 0.38 1.22 ± 0.28 1.32 ± 0.49 1.06 ± 0.28 1.18 ± 0.27
LDL (mg/dL) 1.51 ± 0.26#,▼ 2.81 ± 0.50* 2.44 ± 0.29* 2.11 ± 0.38*,#,▼ 1.71 ± 0.27#,▼ 2.73 ± 0.48*
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also exhibited upregulated TLR4 expression. However, 
decreased expression (recovery toward the levels observed 
in Group C) was observed for Groups I, M, and H (Fig. 2a).
Similar patterns of expression were observed for NF-κB, 
with low expression observed in the nuclei of Kupffer cells 
in hepatic sinusoids in Group C and increased expression 
in hepatocyte nuclei and Kupffer cells in Group D. The 
expression of NF-κB in hepatocyte nuclei was also high in 
Groups L and I, while minimal expression was observed 
in some Kupffer cells in hepatic sinusoids in Group M. 
No clear expression of NF-κB was observed in Group H 
(Fig. 2b).
Lastly, patterns of TNF-α and CD68 expression were 
also similar to those of TLR4, with low expression in 
Group C, increased expression in Groups D and L, and 
reduced expression in Groups M, I, and H (Fig. 2c, d).
Fig. 1  1,25(OH)2D3 exhibited protective effects in livers from dia-
betic rats. a H&E staining (×200) showed obvious inflammatory cell 
infiltration around hepatocytes and diffuse infiltration around the por-
tal vein in diabetic rats. Infiltration of inflammatory cells with stea-
tosis of hepatocytes was observed in diabetic rats treated with insu-
lin. Alleviation of the infiltration of inflammatory cells was observed 
in diabetic rats treated with medium- and high-dose 1,25(OH)2D3. 
b Masson’s trichrome staining (×400) showed colorization around 
perisinusoidal spaces, cells, and the portal area, and the structure of 
the hepatic lobule was abnormal in diabetic rats. The level of inter-
stitial fibrosis decreased, and the structure of the liver was intact in 
diabetic rats treated with high-dose 1,25(OH)2D3
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Therefore, taken together, the results of immunohisto-
chemical analysis indicated that components of the TLR4 
pathway were downregulated by 1,25(OH)2D3 treatment of 
diabetic rats.
RT‑PCR and western blotting analysis
We investigated the mRNA levels of TLR4 signaling path-
way components in the liver tissues. TLR4, NF-κB, and 
TNF-α mRNA levels in the liver tissues of rats in Group D 
were increased compared with those in Group C. Addition-
ally, levels of all transcripts were significantly decreased 
(P < 0.05) in rats in Groups M, H, and I as compared with 
those in rats in Group D. Moreover, comparison of tran-
script levels in Groups M, H, and L demonstrated that 
1,25(OH)2D3 treatment decreased gene expression in a 
dose-dependent manner (Fig. 3a–c). Furthermore, TLR4, 
phospho-NF-κB 65, and TNF-α levels were increased in 
Group D compared with Group C and in Groups H and I 
compared with Group D (Fig. 3d).
Primary hepatocytes were harvested for RT-PCR or 
western blot analysis. TLR4, NF-κB, IL-6, and TNF-α 
mRNA levels were significantly increased in hepatocytes 
in Groups F, L, and L + F compared with those in Group 
C. Moreover, 1,25(OH)2D3 reduced the high fat- or LPS-
induced increase in TLR4, NF-κB, IL-6, and TNF-α mRNA 
levels in primary hepatocytes of Groups L, F, and L + F 
(P < 0.05; Fig. 4a–d). Western blot results showed that 
the levels of TLR4, phospho-NF-κB 65, and TNF-α were 
increased in Groups L, F, and L + F compared with those 
in Group C (P < 0.05). Additionally, the levels of the above 
transcripts were markedly suppressed by 1,25(OH)2D3 in 
primary hepatocytes (Fig. 4e).
Discussion
Diabetes mellitus often co-exists with different metabolic-
related syndromes, such as dyslipidemia, hypertension, and 
NAFLD. In our study, diabetic rats showed abnormal lipid 
profiles and increased serum ALT and CRP levels. Patholog-
ical results showed that obvious inflammation and fibrosis 
occurred in diabetic rats compared with normal rats. Moreo-
ver, results of immunohistochemical staining, RT-PCR, and 
western blotting showed consistent upregulation of TLR4, 
NF-κB, and TNF-α expression in the livers of diabetic rats.
Fig. 2  1,25(OH)2D3 administration downregulated TLR4, NF-κB, 
TNF-α, and CD68 proteins in the liver (magnification, ×200). 
a TLR4 staining was observed in the cytoplasm of hepatocytes and 
Kupffer cells in diabetic rats, with reduced staining observed in rats 
treated with high-dose 1,25(OH)2D3. b NF-κB staining was observed 
in the nuclei of hepatocytes and Kupffer cells in diabetic rats. How-
ever, minimal, discrete staining was observed in Kupffer cells in 
the hepatic sinusoids in rats treated with high-dose 1,25(OH)2D3. 
c TNF-α staining showed brown deposition on the surfaces of 
hepatocytes and Kupffer cells in diabetic rats. The number of posi-
tively stained cells decreased, and the staining became lighter in 
rats treated with high-dose 1,25(OH)2D3. d CD68 staining showed 
that there were more and larger Kupffer cells in diabetic control 
(untreated) rats than in rats treated with insulin or medium- or high-
dose 1,25(OH)2D3
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Vitamin D deficiency is closely associated with many 
hepatic diseases, including NAFLD, alcoholic liver disease, 
viral hepatitis, and hepatocellular carcinoma, as well as liver 
transplantation [8–12]. Patients with biopsy-proven NAFLD 
had lower 25(OH)D3 concentrations than the matched con-
trols, and 25(OH)D3 concentrations were lower in individu-
als with NASH than in those with simple steatosis [13], 
suggesting the need for evaluation of the possible protec-
tive role of vitamin D supplementation in the development 
and progression of NAFLD. Recently, Nakano et al. [14] 
found that sunlight therapy ameliorates hepatocyte inflam-
mation and fibrosis by regulating lipid transfer/metabolic 
proteins and vitamin D3 status. Additionally, Roth et al. 
[8] showed that the severity of NAFLD in rats consum-
ing a vitamin D-deficient diet is increased compared with 
that in rats receiving vitamin D supplementation. In Asia, a 
cross-sectional study of 6567 Korean men found that par-
ticipants with higher levels of serum 25(OH)D3 showed a 
significantly reduced risk for NAFLD compared with the 
low 25(OH)D3 groups [15]. Sharifi et al. [16] divided 53 
patients into two groups in a parallel, double-blind, pla-
cebo-controlled study. The patients were randomly allo-
cated to receive either one oral pearl consisting of vitamin 
D3 (50,000 IU) or a placebo every 14 days for 4 months. 
This study showed that the median serum 25(OH)D3 con-
centration significantly increased in patients who received 
vitamin D. Additionally, improved vitamin D status led to 
amelioration of serum high-sensitivity CRP (hs-CRP) and 
malondialdehyde (MDA) abnormalities. These findings sug-
gested that supplementation with vitamin D may help pre-
vent hepatic diseases. Consistent with these findings, our 
results showed that high-dose 1,25(OH)2D3 administration 
Fig. 3  1,25(OH)2D3 downregulated the expression of components of 
the TLR4 signaling pathway. The relative mRNA expression levels 
of TLR4, NF-κB, and TNF- α were measured in all groups of rats, 
and changes in expression relative to Group C were determined (a–c). 
Western blotting was used to assess the levels of TLR4, phospho-
NF-κB, and TNF-α in all groups of rats (d). *Compared with Group 
C, P < 0.05; #compared with Group D, P < 0.05; ▼compared with 
Group I, P < 0.05
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could significantly protect against liver inflammation and 
fibrosis in diabetic rats. However, some larger, randomized, 
placebo-controlled trials are required to detect the effects of 
vitamin D supplementation for the treatment of NAFLD and 
to determine the optimal levels of vitamin D. Furthermore, 
we found that the expression of TLR4, NF-κB, and TNF-α 
was downregulated by 1,25(OH)2D3 in a dose-dependent 
manner. We also observed differences in CD68 staining 
among groups, indicating changes in Kupffer cell/mac-
rophage numbers. Many of the changes observed in the liver 
were secondary to the changes in Kupffer cell numbers, and 
these alterations may mediate the anti-inflammatory effects 
of high-dose 1,25(OH)2D3 in the liver of diabetic rats. 
Because high-dose 1,25(OH)2D3 may lead to problems such 
as hypercalcemia, we also tested serum calcium and phos-
phate levels. Our results showed that the levels of serum cal-
cium and phosphate in rats treated with 1,25(OH)2D3 were 
not significantly different compared with those in normal 
rats.
We also observed reduced LDL cholesterol levels in rats 
in the high-dose 1,25(OH)2D3 group. Recently, Eflekhari 
et al. [17] found that treatment with 0.5 µg of calcitriol 
(1,25(OH)2D3) per day in patients with T2DM resulted in 
significant reductions in total cholesterol, LDL cholesterol, 
TG, and serum MDA levels. Thus, high-dose 1,25(OH)2D3 
may reduce oxidative stress and improve lipid profiles.
Hepatocytes account for the largest number of cells 
in the liver and are involved in biosynthetic and meta-
bolic processes. These cells can take up and remove LPS 
from portal circulation. In many studies, activation of the 
TLR4-mediated inflammatory pathway in hepatocytes has 
been shown to play an important role in the early stages of 
NAFLD [18]. Therefore, in this study, we treated primary 
hepatocytes with high fat, LPS, and 1,25(OH)2D3, individ-
ually or in combination. Our results showed that high fat 
and LPS treatments significantly increased the expression 
of TLR4, NF-κB, and downstream inflammatory factors, 
while treatment with 1,25(OH)2D3 decreased the expres-
sion of TLR4, NF-κB, and inflammatory factors.
The present investigation demonstrated that 
1,25(OH)2D3 administration could partially protect against 
liver inflammation and fibrosis in diabetic rats in vivo 
and in vitro. The protective effects of this molecule may 
be related to the downregulation of components of the 
Fig. 4  TLR4, NF-κB, IL-6, and TNF-α mRNA levels in hepatocytes. 
a–d The mRNA expression levels of TLR4, NF-κB, IL-6, and TNF-α 
were examined for the different treatment groups. e Protein expres-
sion of TLR4 and TNF-α and phosphorylation levels of NF-κB 65 
were examined by western blotting
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TLR4-mediated inflammation pathway. Intake of vitamin 
D through diet or sun exposure is only one of the many 
variables determining the activity of this pathway. Other 
variables include D binding protein (DBP) levels, the 
local synthesis of 1α, 25(OH)2D3, and vitamin D receptor 
(VDR) expression. Severe liver disease decreases vitamin 
D hydroxylation and albumin and DBP production. All of 
these factors are linked to the low levels of 25(OH)D. In our 
experiments, we found that compared to that observed in 
the control group, levels of ALB in diabetic rats decreased 
significantly. As a limitation of this study, we do not have 
information on the serum concentrations of 25(OH)D3 and 
DBP in different groups of rats. Further studies will be 
required to assess the levels of 25(OH)D, VDR, and DBP 
in rats and to define the mechanisms involved in the down-
regulation of TLR4-mediated inflammation and the side 
effects of high-dose 1,25(OH)2D3 administration. These 
studies should provide valuable insights into the develop-
ment of new treatments for diabetic liver injury.
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